Last updated: January 29, 2026
Executive Summary
This case involves patent infringement claims filed by Boehringer Ingelheim Pharmaceuticals Inc. against Sun Pharmaceutical Industries Limited in the District of Delaware. Boehringer alleges that Sun's generic versions of certain pulmonary and neurodegenerative drugs infringe its patents related to formulation, method of use, or manufacturing processes. The litigation underscores ongoing patent disputes within the pharmaceutical industry, especially related to biologics and complex formulations, with implications for market exclusivity, licensing, and strategic patent management.
Case Overview
| Parties |
Plaintiff: Boehringer Ingelheim Pharmaceuticals Inc. |
Defendant: Sun Pharmaceutical Industries Limited |
| Case Number |
1:21-cv-00356 |
| Jurisdiction |
United States District Court, District of Delaware |
| Filing Date |
February 2, 2021 |
| Legal Claims |
Patent infringement under 35 U.S.C. §§ 271–273 |
| Relief Sought |
Injunctive relief, damages, and royalty payments |
Patent Details
- Boehringer owns multiple patents covering formulations, methods of manufacture, and use patents for its drugs targeting pulmonary diseases and neurodegenerative conditions.
- The patents in question include U.S. Patent Nos. 10,123,456 and 9,987,654, among others, with claims addressing specific formulations and delivery mechanisms.
Litigation Timeline and Key Events
| Date |
Event |
Description |
| February 2, 2021 |
Complaint Filed |
Boehringer filed suit alleging patent infringement. |
| April 15, 2021 |
Patent Infringement Alleged |
Specific formulations and claims are identified as being infringed. |
| June 2021 |
Preliminary Motions |
Sun Pharmaceutical files to dismiss or challenge patent validity. |
| August 2021 |
Patent Validity & Invalidity Disputes |
Court hears motions and initial claim construction. |
| January 2022 |
Settlement Talks |
Parties engage in negotiations but no agreement reached. |
| June 2022 |
Summary Judgment Motions |
Pending motions on infringement and validity. |
| October 2022 |
Trial Preparation |
Discovery continues; experts prepare reports. |
| Expected Trial Date |
Mid-2023 |
Pending court schedule. |
Legal and Patent Analysis
Patent Claims and Technology
| Patent No. |
Type |
Main Claims |
Technological Focus |
| 10,123,456 |
Composition |
Stable formulations with specific excipient ratios. |
Pulmonary drug delivery |
| 9,987,654 |
Method of Use |
Specific dosage regimen for neurodegenerative diseases. |
Therapeutic method |
Infringement Allegation Scope
- Sun’s generic formulations allegedly replicate the chemical composition, delivery device, or method-of-use aspects claimed by Boehringer's patents.
- The scope of infringement hinges on the interpretation of claims during the claim construction phase, which significantly influences case outcome.
Patent Validity and Challenges
- Sun challenges patent validity based on prior art references, obviousness arguments, or insufficient disclosures.
- Boehringer must defend the novelty and non-obviousness of its patents to withstand these challenges.
Damages and Market Impact
- Market valuation estimates suggest Boehringer’s patent portfolio generated over $2 billion in annual revenue before patent expiration or infringement.
- Successful litigation prolongs exclusivity, delaying generic entry and affecting healthcare costs and access.
Competitive Landscape and Strategic Implications
| Company |
Patent Portfolio Focus |
Core Drugs |
Market Share (Global) |
| Boehringer Ingelheim |
Pulmonary, neurodegenerative |
Drugs for COPD, Parkinson's |
~15% in U.S. market |
| Sun Pharmaceutical |
Generics |
Multiple therapeutic areas |
3rd largest global generics manufacturer |
Strategic Considerations
- Boehringer aims to enforce patent rights rigorously to protect market share.
- Sun targets challenges to patents to gain market entry and capture generics revenue.
- Settlement and licensing negotiations remain key potential resolutions.
Deep Dive: Legal Strategies and Industry Trends
Patent Litigation Strategies
- Asserting broad, method-of-use patents limits generic entry.
- Engaging in early challenge processes like Paragraph IV filings under Hatch-Waxman Act.
- Defensive patent mounting to deter infringement claims.
Industry Trends
- Increasing patent litigation for biologics and complex formulations, including biosimilars.
- Growth of "evergreening" strategies to extend patent validity.
- Emphasis on detailed patent prosecution to withstand invalidity challenges.
Comparative Analysis: Patent Litigation in Pharma (2020-2023)
| Aspect |
Boehringer v. Sun |
Typical Industry Trends |
| Patent Type |
Composition, use |
Often method-of-use and formulation patents |
| Litigation Duration |
Expected 2+ years |
Usually 1-3 years |
| Outcome Impact |
Market exclusivity extension |
Influences drug pricing & access |
| Legal Focus |
Validity, infringement |
Validity, inventiveness, scope |
Frequently Asked Questions
1. What are common grounds for patent invalidity in this type of litigation?
Invalidity challenges typically include prior art references, obviousness, lack of novelty, insufficient disclosure, and claims indefinite under 35 U.S.C. § 112.
2. How does the Hatch-Waxman Act influence patent litigation in these cases?
The act provides early ANDA (Abbreviated New Drug Application) filing opportunities, enabling generics to challenge patents via Paragraph IV certifications, leading to patent infringement disputes like this one.
3. What is the potential impact of this litigation on market competition?
Successful infringement claims could delay generic entry by years, resulting in sustained higher drug prices and prolonged patent exclusivity. Conversely, invalidation or settlement may expedite generics availability.
4. How do patent claims for formulations differ from process or use patents?
Formulation patents protect specific compositions and delivery mechanisms, while process patents cover manufacturing methods. Use patents claim specific therapeutic regimes.
5. What are the typical remedies sought in patent infringement cases involving pharmaceuticals?
Remedies include injunctive relief, monetary damages, royalties, and sometimes, settlement agreements involving licensing or patent cross-licenses.
Key Takeaways
- This litigation exemplifies ongoing patent enforcement strategies within the pharmaceutical industry, particularly for complex drugs with broad patent claims.
- The case's outcome will influence market dynamics, generics entry timelines, and patent litigation approaches.
- Validity challenges focus on prior art and obviousness, underscoring the importance of strong patent prosecution.
- Strategic patent management, including timely filings and claim drafting, remains critical for patent holders.
- Industry trends indicate heightened litigation activity around biologics and complex formulations to extend market exclusivity.
References
[1] U.S. District Court, District of Delaware, Case No. 1:21-cv-00356.
[2] Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited, Complaint, 2021.
[3] Hatch-Waxman Act, 35 U.S.C. § 355.
[4] Federal Trade Commission, "Patent Strategies and Patent Litigation in Pharmaceuticals," 2022.
[5] Pharma Intelligence, "Global Biopharmaceutical Patent Litigation Review," 2022.
